Pandemic good news

CDC variant report https://covid.cdc.gov/covid-data-tracker/#variant-proportions Some increase in BA.4.6 and BA.2.75 BA.4.6 Progressive US increase, starting to slowly displace BA.5 US of America (9,526) Canada (1,007) Denmark (500) France (400) Australia (288) Germany (248) Chile (242) Dominican Republic (173), Peru (149), Luxembourg (123), Belgium (102), Israel (101), Italy (94), Ireland (93), Sweden (92), Spain (85), Netherlands (84), Brazil (76), Argentina (68), Japan (67), New Zealand (60), Switzerland (54), Puerto Rico (53), South Africa (53), Ecuador (49), Mexico (35), Colombia (34), Trinidad and Tobago (30), Czech Republic (27), Costa Rica (23), Jamaica (21), Portugal (20), South Korea (19), Austria (17), Botswana (17), Indonesia (13), Sint Maarten (12), Senegal (11) BA.2.75 Some US increase Growth rate is currently 61% per week relative to co-circulating lineages Current US nowcast BA.5 84.8% (UK, 87.2%) BA.4.6 10.3% (UK, 3.3) BA.4 1.8% BF.7 1.7% BA.2.75 1.3% (UK, 1.6%) BA.2 0% (UK, 0.5%) BA.1s 0% Delta 0% Others 0% (UK, 2.4%) XE 0% UK, technical briefing 45 (September 2022) https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1103869/Technical-Briefing-45-9September2022.pdf Contains early data and analysis on emerging variants Findings have a high level of uncertainty Data cut-off of 5 September 2022 BA.5 BA.5 is the predominant circulating variant in the United Kingdom Newly designated variant – V-22SEP-01 (BA.4.6) Omicron sub-lineage BA.4.6 An apparent small growth advantage relative to BA.5. BA.4.6 represented 3.31% of UK samples Preliminary neutralisation data from BA.4.6 Expect some immune escape from BA.4 or BA.5 antibodies There is NO increased risk of hospital admission after BA.4 or BA.5 infection compared to BA.2 infection. Expect some immune escape triple dosed recipients of the Pfizer BNT162b2 vaccine. V-22JUL-01 (BA.2.75) As of 6 September 2022 BA.2.75 in the UK, 1.6% Does seem to have growth advantage over co-circulating lineages of, 61% per week Two sub-lineages of BA.2.75 (BA.2.75.1 and BA.2.75.2) are currently being assessed BA.4/BA.5 Severity A case-control study Risk of being admitted to hospital as an inpatient Among people presenting to emergency care within 14 days of positive test. Comparison, risk of admission with BA.4 or BA.5 versus BA.2 Between 16 March 2022 and 23 August 2022 BA.4 n = 2,530 BA.5 n = 12,026 BA.2 n = 17,022 Adjusted for age, sex, vaccination status, week of test, 2 days of extreme heat There was no difference in the risk of admission between people infected with BA.4 compared to BA.2 There was no difference in the risk of admission between people infected with BA.5 compared to BA.2 Learn more about your ad choices. Visit megaphone.fm/adchoices